PL3040333T3 - Krystaliczne postacie 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4-trifluorometylopirydyno-2-aminy, inhibitora pik3 - Google Patents

Krystaliczne postacie 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4-trifluorometylopirydyno-2-aminy, inhibitora pik3

Info

Publication number: PL3040333T3
Authority: PL; Poland
Prior art keywords: pyridmidinyl; trifluoromethylpyridin; morpholinyl; amine; crystalline forms
Prior art date: 2010-10-01

Application number

PL16151719T

Other languages

English (en)

Inventor

John Vincent Calienni

Marilyn De La Cruz

Dietmar Flubacher

Baoqing Gong

Prasad Koteswara Kapa

Piotr H. Karpinski

Hui Liu

Pascal Michel

Rasmus Mose

Maria Caterina Testa

Liladhar Murlidhar Waykole

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-01

Filing date

2011-09-29

Publication date

2019-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44773179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3040333(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-29 Application filed by Novartis Ag filed Critical Novartis Ag

2019-03-29 Publication of PL3040333T3 publication Critical patent/PL3040333T3/pl

Links

101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pyridine Compounds (AREA)

PL16151719T 2010-10-01 2011-09-29 Krystaliczne postacie 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4-trifluorometylopirydyno-2-aminy, inhibitora pik3 PL3040333T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US38872110P	2010-10-01	2010-10-01
US201161494915P	2011-06-09	2011-06-09
EP16151719.8A EP3040333B1 (en)	2010-10-01	2011-09-29	Crystalline forms of 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluoromethylpyridin-2-amine, a pik3 inhibitor
PCT/US2011/053808 WO2012044727A2 (en)	2010-10-01	2011-09-29	Manufacturing process for pyrimidine derivatives
EP11767362.4A EP2621908A2 (en)	2010-10-01	2011-09-29	Manufacturing process for pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
PL3040333T3 true PL3040333T3 (pl)	2019-03-29

Family

ID=44773179

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16151719T PL3040333T3 (pl)	2010-10-01	2011-09-29	Krystaliczne postacie 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4-trifluorometylopirydyno-2-aminy, inhibitora pik3

Country Status (30)

Country	Link
US (3)	US9181215B2 (pl)
EP (2)	EP3040333B1 (pl)
JP (3)	JP5998145B2 (pl)
KR (2)	KR20130119928A (pl)
CN (3)	CN104945373A (pl)
AR (1)	AR083213A1 (pl)
AU (4)	AU2011308856B2 (pl)
BR (1)	BR112013007123B1 (pl)
CA (1)	CA2813333C (pl)
CL (2)	CL2013000850A1 (pl)
CO (1)	CO6700837A2 (pl)
DK (1)	DK3040333T3 (pl)
EC (1)	ECSP13012596A (pl)
ES (1)	ES2699951T3 (pl)
GT (1)	GT201300080A (pl)
HU (1)	HUE041326T2 (pl)
IL (3)	IL225113A (pl)
LT (1)	LT3040333T (pl)
MX (1)	MX354482B (pl)
MY (1)	MY160785A (pl)
NZ (1)	NZ608285A (pl)
PE (1)	PE20140002A1 (pl)
PH (2)	PH12013500579A1 (pl)
PL (1)	PL3040333T3 (pl)
PT (1)	PT3040333T (pl)
RU (2)	RU2015150728A (pl)
SG (1)	SG188439A1 (pl)
SI (1)	SI3040333T1 (pl)
TW (1)	TWI540133B (pl)
WO (1)	WO2012044727A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2726074B1 (en)	2011-07-01	2018-04-04	Novartis AG	Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
BR112014007310A2 (pt)	2011-09-27	2017-04-04	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
UY34632A (es)	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
AU2013336807B2 (en) *	2012-10-23	2016-10-27	Novartis Ag	Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6387360B2 (ja)	2013-03-14	2018-09-05	ノバルティスアーゲー	変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
US9318944B2 (en)	2013-04-29	2016-04-19	Rockwell Automation Technologies, Inc.	Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en)	2013-10-01	2016-03-22	Rockwell Automation Technologies, Inc.	Method and apparatus for detecting AFE filter capacitor degradation
CN104557872B (zh) *	2013-10-16	2017-05-24	上海璎黎药业有限公司	稠合杂环化合物、其制备方法、药物组合物和用途
ES2713452T3 (es) *	2014-04-22	2019-05-21	Univ Basel	Proceso de fabricación para derivados de triazina, pirimidina y piridina
CN105085476B (zh) *	2014-11-24	2018-03-09	苏州晶云药物科技有限公司	5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
CN107001348B (zh) *	2014-12-17	2019-10-11	上海海雁医药科技有限公司	2-吗啉-4,6-二取代的嘧啶衍生物、其制法与医药上的用途
US9481665B2 (en) *	2015-03-13	2016-11-01	Yong Xu	Process for preparing PI3K inhibitor buparsilib
WO2016151501A1 (en)	2015-03-25	2016-09-29	Novartis Ag	Pharmaceutical combinations
CN105001151B (zh) *	2015-08-28	2017-07-14	苏州明锐医药科技有限公司	布帕尼西中间体及其制备方法
CN106543140A (zh) *	2015-09-21	2017-03-29	苏州晶云药物科技有限公司	5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
MY196817A (en) *	2015-12-16	2023-05-03	Genentech Inc	Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
CN106905294A (zh) *	2016-07-08	2017-06-30	苏州科睿思制药有限公司	5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) *	2017-08-03	2018-03-13	上海厚璞生物科技有限公司	一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) *	2019-04-30	2021-08-03	合肥工业大学	一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6124476A (en)	1998-04-17	2000-09-26	Symyx Technologies, Inc.	Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) *	2002-11-11	2006-02-15	拜耳医药保健股份公司	作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
EA013811B1 (ru)	2002-11-21	2010-08-30	Новартис Вэксинес Энд Дайэгностикс, Инк.	2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
AU2007287428B2 (en)	2006-08-24	2011-08-11	Astrazeneca Ab	Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008098058A1 (en)	2007-02-06	2008-08-14	Novartis Ag	Pi 3-kinase inhibitors and methods of their use
WO2009066084A1 (en)	2007-11-21	2009-05-28	F. Hoffmann-La Roche Ag	2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
AU2010247397B2 (en) *	2009-05-15	2012-07-12	Novartis Ag	Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound

2011
- 2011-09-29 SG SG2013016837A patent/SG188439A1/en unknown
- 2011-09-29 JP JP2013531796A patent/JP5998145B2/ja active Active
- 2011-09-29 MX MX2013003507A patent/MX354482B/es active IP Right Grant
- 2011-09-29 CN CN201510157366.4A patent/CN104945373A/zh active Pending
- 2011-09-29 RU RU2015150728A patent/RU2015150728A/ru unknown
- 2011-09-29 AU AU2011308856A patent/AU2011308856B2/en not_active Ceased
- 2011-09-29 KR KR1020137011172A patent/KR20130119928A/ko not_active Ceased
- 2011-09-29 DK DK16151719.8T patent/DK3040333T3/da active
- 2011-09-29 PL PL16151719T patent/PL3040333T3/pl unknown
- 2011-09-29 PH PH1/2013/500579A patent/PH12013500579A1/en unknown
- 2011-09-29 EP EP16151719.8A patent/EP3040333B1/en active Active
- 2011-09-29 NZ NZ608285A patent/NZ608285A/en not_active IP Right Cessation
- 2011-09-29 ES ES16151719T patent/ES2699951T3/es active Active
- 2011-09-29 SI SI201131619T patent/SI3040333T1/sl unknown
- 2011-09-29 WO PCT/US2011/053808 patent/WO2012044727A2/en not_active Ceased
- 2011-09-29 PT PT16151719T patent/PT3040333T/pt unknown
- 2011-09-29 PE PE2013000654A patent/PE20140002A1/es active IP Right Grant
- 2011-09-29 BR BR112013007123-0A patent/BR112013007123B1/pt active IP Right Grant
- 2011-09-29 LT LTEP16151719.8T patent/LT3040333T/lt unknown
- 2011-09-29 HU HUE16151719A patent/HUE041326T2/hu unknown
- 2011-09-29 EP EP11767362.4A patent/EP2621908A2/en not_active Withdrawn
- 2011-09-29 CA CA2813333A patent/CA2813333C/en active Active
- 2011-09-29 MY MYPI2013000811A patent/MY160785A/en unknown
- 2011-09-29 US US13/825,880 patent/US9181215B2/en active Active
- 2011-09-29 RU RU2013120326/04A patent/RU2576619C2/ru active
- 2011-09-29 KR KR1020187032263A patent/KR20180123586A/ko not_active Ceased
- 2011-09-29 AR ARP110103595A patent/AR083213A1/es unknown
- 2011-09-29 CN CN201180047753.2A patent/CN103140479B/zh active Active
- 2011-09-29 CN CN201510156027.4A patent/CN104987321A/zh active Pending
- 2011-09-30 TW TW100135673A patent/TWI540133B/zh active
2013
- 2013-03-07 IL IL225113A patent/IL225113A/en unknown
- 2013-03-22 CO CO13057091A patent/CO6700837A2/es unknown
- 2013-03-22 GT GT201300080A patent/GT201300080A/es unknown
- 2013-03-28 CL CL2013000850A patent/CL2013000850A1/es unknown
- 2013-04-30 EC ECSP13012596 patent/ECSP13012596A/es unknown
2014
- 2014-06-19 IL IL233282A patent/IL233282A/en unknown
2015
- 2015-02-24 AU AU2015200938A patent/AU2015200938B2/en not_active Ceased
- 2015-02-24 AU AU2015200936A patent/AU2015200936A1/en not_active Abandoned
- 2015-03-30 IL IL238046A patent/IL238046A/en not_active IP Right Cessation
- 2015-04-27 CL CL2015001088A patent/CL2015001088A1/es unknown
- 2015-05-06 US US14/705,013 patent/US9359326B2/en not_active Expired - Fee Related
- 2015-07-20 PH PH12015501585A patent/PH12015501585A1/en unknown
- 2015-10-23 AU AU2015246141A patent/AU2015246141B2/en not_active Ceased
- 2015-12-17 JP JP2015246501A patent/JP2016128414A/ja active Pending
- 2015-12-17 JP JP2015246502A patent/JP2016106091A/ja active Pending
2016
- 2016-05-06 US US15/147,986 patent/US9452994B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20130119928A (ko)	2013-11-01
US20160251334A1 (en)	2016-09-01
MX354482B (es)	2018-03-07
HUE041326T2 (hu)	2019-05-28
EP2621908A2 (en)	2013-08-07
PT3040333T (pt)	2018-12-04
US9359326B2 (en)	2016-06-07
PH12013500579A1 (en)	2016-06-10
JP2013541536A (ja)	2013-11-14
CN103140479A (zh)	2013-06-05
PE20140002A1 (es)	2014-01-21
RU2015150728A (ru)	2019-01-15
MY160785A (en)	2017-03-15
AU2015246141B2 (en)	2016-07-07
AU2015200938A1 (en)	2015-03-12
IL233282A (en)	2016-08-31
US20150232446A1 (en)	2015-08-20
CN104987321A (zh)	2015-10-21
AU2015200938B2 (en)	2015-11-19
SI3040333T1 (sl)	2019-01-31
DK3040333T3 (da)	2019-01-02
ECSP13012596A (es)	2013-07-31
MX2013003507A (es)	2013-05-20
EP3040333A1 (en)	2016-07-06
CL2015001088A1 (es)	2015-07-10
SG188439A1 (en)	2013-05-31
CN103140479B (zh)	2015-04-08
AU2011308856A1 (en)	2013-03-28
GT201300080A (es)	2014-07-18
NZ608285A (en)	2014-06-27
BR112013007123A2 (pt)	2016-06-14
CA2813333C (en)	2019-01-15
US9452994B2 (en)	2016-09-27
EP3040333B1 (en)	2018-09-12
IL238046A (en)	2016-08-31
ES2699951T3 (es)	2019-02-13
AR083213A1 (es)	2013-02-06
IL233282A0 (en)	2014-08-31
AU2011308856B2 (en)	2015-04-23
RU2013120326A (ru)	2014-11-20
TWI540133B (zh)	2016-07-01
CA2813333A1 (en)	2012-04-05
KR20180123586A (ko)	2018-11-16
AU2015246141A1 (en)	2015-11-12
RU2576619C2 (ru)	2016-03-10
LT3040333T (lt)	2018-12-10
CL2013000850A1 (es)	2013-09-27
JP2016128414A (ja)	2016-07-14
US9181215B2 (en)	2015-11-10
HK1220686A1 (en)	2017-05-12
US20130225571A1 (en)	2013-08-29
TW201215605A (en)	2012-04-16
IL225113A (en)	2016-08-31
PH12015501585A1 (en)	2015-09-21
CO6700837A2 (es)	2013-06-28
JP5998145B2 (ja)	2016-09-28
JP2016106091A (ja)	2016-06-16
AU2015200936A1 (en)	2015-03-12
BR112013007123B1 (pt)	2021-11-09
WO2012044727A2 (en)	2012-04-05
WO2012044727A3 (en)	2012-06-07
CN104945373A (zh)	2015-09-30

Publication	Publication Date	Title
PT3040333T (pt)	2018-12-04	Formas cristalinas de 5- (2,6-di-4-morfolinil-4- pirimidinilo) -4-trifluorometilpiridina-2-amina, um inibidor de pik3
IL295518B1 (en)	2023-07-01	Heterocyclic compounds used as pdk1 inhibitors
IL239081B (en)	2018-05-31	Benzoxazepine pi3k inhibitor compound
GB201004311D0 (en)	2010-04-28	New enzyme inhibitor compounds
GB201001075D0 (en)	2010-03-10	Crystalline forms
IL209196A0 (en)	2011-01-31	A crystalline form of posaconazole
PT2611779T (pt)	2016-11-21	Formas cristalinas de um inibidor do fator xa
ZA201000829B (en)	2010-12-29	Oxadiazole- and oxazole-substituted benzamidazole-and indole-derivatives as dgat1 inhibitors
EP2519508A4 (en)	2013-05-29	METALLO ENZYME INHIBITOR COMPOUNDS
PL2527340T3 (pl)	2017-01-31	Związek piperazynowy wykazujący efekt hamowania pgds
IL218967A0 (en)	2012-07-31	Phenyloxadiazole derivatives as pgds inhibitors
PL2578595T3 (pl)	2017-10-31	Krystaliczna lewoizowalerylospiramycyna I
ZA201100694B (en)	2013-04-24	Salts of hiv inhibitor compounds
PL2085445T3 (pl)	2016-08-31	Zastosowanie linera
IL223584A0 (en)	2013-03-05	Crystalline form of a 3-phenoxymethylpyrrolidine compounds
ZA201104319B (en)	2012-03-28	Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL213935A0 (en)	2011-07-31	Novel heterocyclic compounds as metap-2 inhibitors
GB2461167B (en)	2012-12-26	Novel amidoxime derivatives
AP2717A (en)	2013-07-31	Mono-hydrochloric salts of an inhibitor of histonedeacetylase
GB201004308D0 (en)	2010-04-28	New inhibitor compounds
SI2307435T1 (sl)	2012-10-30	Soli spojin, inhibitorjev HIV
PL386893A1 (pl)	2010-07-05	Inhibitor parafin
AU2010904580A0 (en)	2010-10-28	Non-toxic locust-flight inhibitor
GB0817164D0 (en)	2008-10-29	Crystalline forms